Abstract Number: 1281 • ACR Convergence 2020
Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus
Background/Purpose: One in four Medicare hospitalizations with systemic lupus erythematosus (SLE) results in readmission within 30 days, with “injuries and poisonings” as the second most…Abstract Number: 1297 • ACR Convergence 2020
Lupus Antibodies in Relation to Malignancy
Background/Purpose: Systemic Lupus Erythematosus (SLE) a chronic inflammatory autoimmune disease that has the potential to affect every organ system. Studies have shown increased risk of…Abstract Number: 1507 • ACR Convergence 2020
Longitudinal Analysis of ANA Assay Performance in SLE from the SLICC Inception Cohort
Background/Purpose: Anti-nuclear antibodies (ANA) are important biomarkers for the diagnosis and classification of systemic lupus erythematosus (SLE). However, emerging data from cross-sectional studies suggest variation…Abstract Number: 1634 • ACR Convergence 2020
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH…Abstract Number: 1683 • ACR Convergence 2020
Ready or Not? Measuring Readiness for Transition to Adult Care in Adolescents with JIA & jSLE
Background/Purpose: Transitioning from pediatric to adult care represents a particularly vulnerable period among patients with JIA and jSLE. The shift to adult care is often…Abstract Number: 1795 • ACR Convergence 2020
Intracellular Homocysteine and Homocysteine Metabolites in Systemic Lupus Erythematosus (SLE)
Background/Purpose: In SLE, homocysteine has been shown to be a potentially modifiable, independent risk factor for stroke and thrombotic events. All previous epidemiological studies used…Abstract Number: 1813 • ACR Convergence 2020
A Comprehensive Method to Study Environmental Chemicals in Serum in Patients with SLE
Background/Purpose: Environmental exposures may play a substantial role in the pathogenesis of Systemic Lupus Erythematosus (SLE), however it has been challenging to measure and capture…Abstract Number: 1829 • ACR Convergence 2020
Lupus Disease Activity After Cessation of Anifrolumab Treatment During the Phase 2b MUSE Trial Follow-up Period
Background/Purpose: In the randomized, double-blind, phase 2b MUSE trial, anifrolumab reduced disease activity vs placebo across multiple endpoints in patients with moderately to severely active…Abstract Number: 1847 • ACR Convergence 2020
Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus
Background/Purpose: Morning stiffness and fatigue are common symptoms in patients with SLE. Increased cytokines and disturbed sleep patterns may contribute to morning symptoms and fatigue…Abstract Number: 0249 • ACR Convergence 2020
Validation of the SIMPLE Index for Disease Activity of Systemic Lupus Erythematosus in Chinese Patients
Background/Purpose: The SIMPLE (SIMple Disease Assessment for People with Lupus Erythematosus) index is a composite numeric tool that captures disease activity from patients’ self-assessment with…Abstract Number: 0266 • ACR Convergence 2020
The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can present with acute disease flares/exacerbations during pregnancy and postpartum period1. These flares can cause adverse pregnancy outcomes…Abstract Number: 0282 • ACR Convergence 2020
Expression of the cGAMP Transporter SLC19A1 Is Altered in Systemic Lupus Erythematosus
Background/Purpose: Inappropriate sensing of nucleic acids leading to enhanced type I interferon (IFN) induction is a hallmark of SLE, contributing to breakdown of immune tolerance…Abstract Number: 0300 • ACR Convergence 2020
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…Abstract Number: 0495 • ACR Convergence 2020
Epstein Barr Virus (EBV), an Etiologic Factor for Systemic Lupus Erythematosus (SLE), Interacts with SLE Risk Loci Through EBV-encoded Transcription Co-factors (co-TFs)
Background/Purpose: SLE affects millions worldwide. The etiology of this complex autoimmune disease is the consequence of both strong genetic and environmental components. Genome-wide association studies…Abstract Number: 0616 • ACR Convergence 2020
Correlation Between Disease Activity and Perceived Economic Barriers to Care in a Population of African American Women with Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex, multifactorial disease with heterogeneous presentation. Disease activity – the number and severity of symptoms – can be…
- « Previous Page
- 1
- …
- 77
- 78
- 79
- 80
- 81
- …
- 119
- Next Page »